Original Research J Clin Psychiatry May 2026

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Patients with chronic suicidal ideation often remain symptomatic despite multiple adequate antidepressant trials, and most psychedelic studies have excluded them entirely. This study addresses whether a single psilocybin session with psychological support can produce rapid antisuicidal benefit in a population with persistent, treatment-resistant suicidal thoughts. FAQ What did this study find about psilocybin for chronic suicidal ideation? 10 questions
Key Takeaways The primary antisuicidal signal was substantial by week 3, with a mean MSSI reduction of 13.95 points and Cohen d = 1.73 after a single 25-mg dose delivered with structured preparation and integration. 6 takeaways Clinical Guide How do clinicians identify which patients with major depressive disorder and chronic suicidal ideation fit the study-supported psilocybin treatment population? 6 steps Clinical Guide How should clinicians monitor response and safety after a single psilocybin dose in patients with chronic suicidal ideation? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe